CN1135895A - 一种治疗妇女生殖道疾病的药物及其用途 - Google Patents
一种治疗妇女生殖道疾病的药物及其用途 Download PDFInfo
- Publication number
- CN1135895A CN1135895A CN95110773A CN95110773A CN1135895A CN 1135895 A CN1135895 A CN 1135895A CN 95110773 A CN95110773 A CN 95110773A CN 95110773 A CN95110773 A CN 95110773A CN 1135895 A CN1135895 A CN 1135895A
- Authority
- CN
- China
- Prior art keywords
- blatta seu
- extract
- seu periplaneta
- female genital
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000010099 disease Diseases 0.000 title abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 4
- 210000005002 female reproductive tract Anatomy 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title description 5
- 229940079593 drug Drugs 0.000 title description 2
- 230000003628 erosive effect Effects 0.000 claims abstract description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract description 3
- 201000010881 cervical cancer Diseases 0.000 claims abstract description 3
- 241000238659 Blatta Species 0.000 claims description 52
- 241000238661 Periplaneta Species 0.000 claims description 52
- 208000016908 Female Genital disease Diseases 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 14
- -1 effervescent Substances 0.000 abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 4
- 241001674044 Blattodea Species 0.000 abstract description 3
- 206010046914 Vaginal infection Diseases 0.000 abstract description 2
- 201000008100 Vaginitis Diseases 0.000 abstract description 2
- 239000000829 suppository Substances 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 abstract 1
- 238000011084 recovery Methods 0.000 description 13
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 4
- FIGVVZUWCLSUEI-UHFFFAOYSA-N tricosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCC FIGVVZUWCLSUEI-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 240000000233 Melia azedarach Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- GLKCOBIIZKYKFN-UHFFFAOYSA-N 2-aminopteridine-4,7-diol Chemical compound N1=CC(O)=NC2=NC(N)=NC(O)=C21 GLKCOBIIZKYKFN-UHFFFAOYSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- 241000238660 Blattidae Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 208000015817 Infant Nutrition disease Diseases 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000238675 Periplaneta americana Species 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 241001502500 Trichomonadida Species 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 239000002917 insecticide Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- YKNWIILGEFFOPE-UHFFFAOYSA-N pentacosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC YKNWIILGEFFOPE-UHFFFAOYSA-N 0.000 description 2
- 239000003016 pheromone Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 description 1
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000238657 Blattella germanica Species 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 108010075027 Cytochromes a Proteins 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 241000086550 Dinosauria Species 0.000 description 1
- 208000003656 Electric Burns Diseases 0.000 description 1
- GWHRSRIPLDHJHR-UHFFFAOYSA-N Epishyobunon Natural products CC(C)C1CCC(C)(C=C)C(C(C)=C)C1=O GWHRSRIPLDHJHR-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 108010025252 Kassinin Proteins 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001510004 Periplaneta australasiae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- GWHRSRIPLDHJHR-GZBFAFLISA-N Shyobunon Natural products CC(C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1=O GWHRSRIPLDHJHR-GZBFAFLISA-N 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241001649251 Supella Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- YDLBHMSVYMFOMI-SDFJSLCBSA-N germacrene Chemical compound CC(C)[C@H]1CC\C(C)=C\CC\C(C)=C\C1 YDLBHMSVYMFOMI-SDFJSLCBSA-N 0.000 description 1
- 229930001612 germacrene Natural products 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- KVFSFBCTIZBPRK-KGDVWTLMSA-N periplanone b Chemical compound C([C@H](/C=C/C(=C)C[C@H]1O[C@H]11)C(C)C)C(=O)[C@]21CO2 KVFSFBCTIZBPRK-KGDVWTLMSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- VURKRJGMSKJIQX-UHFFFAOYSA-N xanthopterin Chemical compound N1C(=O)C=NC2=C1C(=O)N=C(N)N2 VURKRJGMSKJIQX-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及蟑螂乙醇提取物在治疗妇女生殖道疾病方面的新用途。该提取物适量加辅料制成栓剂、泡腾剂、片剂、膜剂、滴剂等剂型，在治疗宫颈糜烂、阴道炎、宫颈癌等症方面，疗程短，疗效好，并较少毒副作用。
Description
技术领域
本发明涉及蟑螂醇提取物制备的药物组合物在治疗妇女生殖道疾病的应用。
背景技术
蟑螂药用，在我国《本草》中已有记载，蟑螂有活血散瘀，解毒消疳，利水消肿等功能。主治症瘕积聚，小儿疳积，脚气水肿等。我国民间也有用其治跌打损伤，蛇虫咬伤等。由此可见，蟑螂自身的药用价值很高。过去人们常把蟑螂看成一种害虫，是有一定的偏见。在云南省白族地区少数民族利用蟑螂治疗烧伤，是当地草医的祖传秘方。根据民间使用结果，云南利用蟑螂研究出一种特效治疗烧伤的药品-康复新滴剂，对各种烧伤有效率这98.2％，福建省福州制药厂利用蟑螂研制出治疗肝癌的药品-消症益肝片，其有效率这89％。国内贵州医学院利用蟑螂油治疗癌症发现它对S180，肝癌等均有抑制作用。国外对蟑螂的研究，也有利用corporacardiace治疗心脏病等。
对蟑螂的化学成份，研究得比较详细。据文献报道，蟑螂淋巴含糖蛋白。海藻糖(trehalose)，肌醇(inositol)，原儿茶酸葡糖甙(protocatechuic acid glucoside)；角皮脂中含13-甲醛廿五烷(13-methy pentacosant)，正一廿三烷(n-tricosane)，脂的抗氧化剂，原儿茶酸，原儿茶醛，3、4-＝羟基苯乙醇，2一羟基-3′，4′-＝羟基苯乙酮，苯甲酸，水杨酸等。角皮和肌肉中含多种氨基酸，甘氨酸，丙氨酸、丝氨酸，苏氨酸，缬氨酸，亮氨酸，异亮氨酸，酪氨酸，组氨酸，赖氨酸，精氨酸，脯氨酸，胱氨酸，牛磺酸，天冬酰氨和细胞色素a、b、c等。蟑螂还含有多种信息素，有蜚蠊酮B(peripanoneB)，germacrene D-1，2-epoxyde，白葛酮(shyobunone)，龙脑乙酸酯等，此外蟑螂还含有多种信息素、神经介质肽和神经色酮C、D，异黄蝶呤，黄蝶呤，5-羟色胺，多巴胺，r-氨基丁酸，软骨素(chondroitin)，皮肤素(dermantan)，硫酸角质素，透明质酸(hyaluromic acid)等。
蟑螂古称蜚蠊，早在3亿5千万年前就在地球上立足。漫长的沧桑巨变，恐龙等庞然大物消失了，而蟑螂却以其顽强的生命力，繁衍生息至今，其足迹遍及世界各地。据科学家考证，蟑螂是地球上最古老的生物之一，已生存3.5亿年之久，但其形成和生活习性至今无多大变化。美国曾发动一场年耗资6亿5千万美元，用化学杀虫剂来消灭蟑螂的活动，结果失败，蟑螂仍然生存下来。在美国原子弹爆炸试验中，有许多被试验的动物和生物，结果只有蟑螂损失最小，除眼被强光刺瞎外，其它吃喝、打斗、求爱等行动照旧，而且还繁衍出健康的后代。国内北京有一大医院，在近35年间，不断的喷洒杀虫药物，每次杀死的蟑螂都可成桶的提倒，尽管如此，蟑螂仍未绝迹。蟑螂如此顽强的生命力，也为科学家们开发和利用提供了基础，现代科学发展到今天，传统观念应该发生变化。过去害虫的功过利害，人们正在重新评说。
蟑螂是一种原始昆虫，在地球上至少存在了3.5亿年，从化石中发现，古今蟑螂虫体无多大的进化，自然界的生存规律是优胜劣汰，蟑螂不被淘汰，还是具有惊人的免疫系数。包括同种异体移植免疫，能产生类似抗体的物质对付其它昆虫毒液，还具备一种细胞传递免疫力。
蟑螂中还分离出两种神经肽，一种是白细胞磺胺激肽，另一种是它的衍生物。它和人体的激素-促胃液素II十分相似。其氨基酸程序竟有55％类同。这种肽的衍生物氨基酸程序与人体另一种激素-缩胆液素有40％以上相似。它们的分子中都含有硫酸盐基因，而这种基因在其它激素中是相当罕见的。这两种激素是经历了5亿年的漫长历史之后，变化还是那么渺小，说明它们是走得最慢的分子钟之一。这个事实也告诉我们，低级生物和高级生物之间，在生化组成和功能效应方面，都存在千丝万缕的联系。也是“生命同一性”的表现形式。
上述可以看出，蟑螂做为活化石，能否像植物银杏一样，被国内外睹目呢？答案是肯定的。自然界中的任何事物都有二重性。做为害虫，是它传播疾病的方面，但另一方面还未被众人认识。
因此，开发和利用蟑螂，变害为宝，是本发明的目的。
发明内容
本发明的目的在于提供蟑螂提取物在制备治疗妇女生殖道疾病药物中的应用。
本发明的另一目的在于提供含有上述蟑螂提取物治疗妇女生殖道疾病的药物组合物。
本发明的再一目的在于提供上述蟑螂提取物用于治疗妇女生殖道疾病的方法。
本发明涉及蟑螂提取物在制备治疗妇女生殖道疾病的应用，其蟑螂(periplaneta australasiae)为蜚蠊科(Blattidae)，德国小蠊(Blattella germanica)、热带蠊(supella supellecti-lum)、东方蠊(B·orientalis)、澳洲蠊(p·australasiae)和美洲大蠊(P·americana)。
其中，更优选的种为澳洲蠊(P·australasiae)和美洲大蠊(P·americana)。
上述蟑螂提取物，包括多肽、氨基酸、多元醇等，经过药理实验证实，有明显地促进肉芽组织增生作用，重复性好，对小鼠电烧伤有明显的治疗作用，对家兔皮肤自发性感染性溃疡有显著地治疗作用。有抗肿瘤作用，对S-180抑制率，有量效关系，剂量越大，抑制率越高。能增加机体的免疫力和细胞免疫力。毒理实验证实，小鼠口服半数致死量10g/kg以上。小鼠静脉注射为3069±523mg/kg。长期毒性和致突变，致畸试验结果阴性。患者外用，对宫颈糜烂患者，轻者用1-2次即愈。创面修复快，患者无任何不良感觉，中、重患者3-7次痊愈，疗效独特，疗程短，疗效好。
本发明进一步涉及一种治疗妇女生殖道疾病的药物组合物，其中含有有效剂量的上述蟑螂提取物。本发明的蟑螂提取物可根据现有技术制成各种剂型，其中可含有药物学上可接受的载体，赋形剂或其他添加剂。如制成口服液、栓剂、泡腾剂、片剂、膜剂、滴剂等。但口服的有效剂量略高于外用剂量，疗效低于外用剂量，故优选外用剂型。优选上述蟑螂提取物在甘油中。
上述蟑螂提取物，在治疗妇女生殖道疾病的应用中，当外用时，有效剂量为该提取的0.1到5％。
本发明涉及的上述蟑螂提取物，在治疗妇女生殖道疾病的应用中，用于治疗妇女生殖炎症时包括宫颈糜烂和阴道炎等，用于治疗生殖道肿瘤时，包括宫颈癌等。
采用本发明的蟑螂提取物，在治疗妇女生殖道疾病的应用中，尤其是生殖道炎症时，疗效快，疗程短，毒副作用小，痊愈率高。
本发明还涉及一种治疗妇女生殖道疾病的方法，包括口服和外用上述蟑螂提取物的有效剂量。
本发明最佳实施方式
实施例1
1份蟑螂提取物溶解2％甘油溶液400份和Azone0.1-2％中，使溶液成含0.25％的蟑螂提取物。
实施例2
1份蟑螂提取物溶解在2％甘油溶液200份和Azone0.1-2％中，使溶液成含0.5％的蟑螂提取物。
实施例3
1份蟑螂提取物溶解在1％-2％甘油溶液100份和Azone0.1-2％中，使溶液成含1％的蟑螂提取物。
实施例4
1份蟑螂提取物溶解在1％甘油溶液50份和Azone0.1-2％中，使溶液成含2％蟑螂提取物。
实验例
病例1-16：
病例1-16为23-42岁的女性。14例I、II、III度宫颈糜烂患者，2例为阴道滴虫患者。患病时间3个月-15年不等。治疗天数3-10天不等，治疗次数2-10次不等。给药方式均为外用，自觉症状和他觉症状消失。详细情况见表1。
典型病例之一：
23岁患者，病程3个月，轻度宫颈糜烂，涂抹一次后，粘膜修复，第二天用药时，已完好如初。
工业应用性
本发明对蟑螂提取物新用途的发明可将该类提取物用于制备治疗妇女生殖道疾病的药物。
表1 蟑螂提取物治疗宫颈糜烂
| 病例号 | 年龄 | 病程 | 糜烂分度 | 治疗次数 | 治疗天数 | 疗效 |
| 12345678910111213141516 | 23262727282828282929303030303742 | 3m8m1y2y6m2y3y5y3y4y5y1y3y7y12y15y | III+IIIII+滴虫II+II+II+II+I+滴虫IIIIIIII+ | 233527677864510108 | 34573109101010981010108 | 痊愈痊愈痊愈痊愈痊愈显效痊愈痊愈痊愈痊愈痊愈痊愈痊愈显效显效痊愈 |
Claims (6)
1、蟑螂提取物制备的药物组合物在治疗妇女生殖道疾病的用途。
2、根据权利要求1所述的应用，其特征为该提取物的成份主要为肽类、氨基酸类和多元醇类等。
3、根据权利要求1所述的应用，其特征为该提取物治疗妇女生殖道炎症方面的应用，主要为宫颈糜烂和阴道炎的应用。
4、根据权利要求1所述的应用，其特征为该提取物治疗妇女生殖道肿瘤方面的应用。主要为宫颈癌。
5、根据权利要求1所述的应用，其特征在于该提取物治疗妇女生殖道疾病的药物组合物有效剂量为提取物的0.25％～5％。
6、根据权利要求1所述的应用，其特征在于该提取物制备的药物组合物用于治疗妇女生殖道疾病的方法为外用和口服。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95110773A CN1135895A (zh) | 1995-05-18 | 1995-05-18 | 一种治疗妇女生殖道疾病的药物及其用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95110773A CN1135895A (zh) | 1995-05-18 | 1995-05-18 | 一种治疗妇女生殖道疾病的药物及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1135895A true CN1135895A (zh) | 1996-11-20 |
Family
ID=5078119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN95110773A Pending CN1135895A (zh) | 1995-05-18 | 1995-05-18 | 一种治疗妇女生殖道疾病的药物及其用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1135895A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006056097A1 (fr) * | 2004-11-23 | 2006-06-01 | Weichang You | Composition pharmaceutique utilisee dans le traitement de la demence senile |
| CN101829193A (zh) * | 2010-05-25 | 2010-09-15 | 耿福能 | 一种治疗宫颈糜烂的药物组合物及其制备方法 |
| CN101254212B (zh) * | 2008-03-25 | 2010-11-17 | 浙江大学 | 美洲大蠊提取物有效部位在制备治疗生殖器疱疹药物中的应用 |
| CN102949373A (zh) * | 2012-11-04 | 2013-03-06 | 耿福能 | 一种浴足泡腾片及其制备方法 |
-
1995
- 1995-05-18 CN CN95110773A patent/CN1135895A/zh active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006056097A1 (fr) * | 2004-11-23 | 2006-06-01 | Weichang You | Composition pharmaceutique utilisee dans le traitement de la demence senile |
| CN101254212B (zh) * | 2008-03-25 | 2010-11-17 | 浙江大学 | 美洲大蠊提取物有效部位在制备治疗生殖器疱疹药物中的应用 |
| CN101829193A (zh) * | 2010-05-25 | 2010-09-15 | 耿福能 | 一种治疗宫颈糜烂的药物组合物及其制备方法 |
| CN101829193B (zh) * | 2010-05-25 | 2012-05-30 | 耿福能 | 一种治疗宫颈糜烂的药物组合物及其制备方法 |
| CN102949373A (zh) * | 2012-11-04 | 2013-03-06 | 耿福能 | 一种浴足泡腾片及其制备方法 |
| CN102949373B (zh) * | 2012-11-04 | 2014-07-09 | 耿福能 | 一种浴足泡腾片及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shikov et al. | Medicinal plants from the 14th edition of the Russian Pharmacopoeia, recent updates | |
| Liu et al. | The gastroprotective effect of small molecule oligopeptides isolated from Walnut (Juglans regia L.) against ethanol-induced gastric mucosal injury in rats | |
| Faridi et al. | Beneficial effects of hydroalcoholic extract of saffron in alleviating experimental autoimmune diabetes in C57bl/6 mice | |
| EP2175836A2 (en) | Liposome composition | |
| CN102228479A (zh) | 一种治疗口腔疾病的药物及其制备方法 | |
| Muhammad et al. | Anti-hyperglycemic activity of solvents extract of Khaya senegalensis stem bark in alloxan induced diabetic rats | |
| Melnyk et al. | Current knowledge on interactions of plant materials traditionally used in skin diseases in Poland and Ukraine with human skin microbiota | |
| CN1100945A (zh) | 广谱蛇伤解毒药 | |
| CN1135895A (zh) | 一种治疗妇女生殖道疾病的药物及其用途 | |
| ZANGENEH et al. | Evaluation of the anti-anemic potential of Glycyrrhiza glabra aqueous extract in Phenylhydrazine-treated rats | |
| Bone et al. | Echinacea: When should it be used | |
| CN101054414A (zh) | 鹿茸表皮生长因子(deer egf)提取及其制备方法 | |
| Nwangwa | Effects of Garcinia kola on the lipid profile of alloxan-induced diabetic wistar rats | |
| CN1348788A (zh) | 治疗慢性咽炎的药物及其制备方法 | |
| Chakraborty et al. | Nutraceutical products from seaweeds-wonder herbs of the oceans | |
| CN1947744A (zh) | 治疗牛皮癣的外用中药酊剂 | |
| CN1247227C (zh) | 一种治疗螨虫感染性皮肤疾病的外用脂质体制剂 | |
| CN1247222C (zh) | 治疗艾滋病的药物组合物 | |
| CN103638065A (zh) | 大胡蜂属昆虫的镇痛抗炎有效部位及其制备方法和用途 | |
| CN1240420C (zh) | 解毒药物 | |
| Shivasaravanan et al. | Effect Of Homoeopathic Ultra Dilutions Of Allium Sativum 30CH, 200CH In Hyperlipidemia On High Fat Diet Induced Experimental Male Albino Wistar Rats | |
| RU2306144C1 (ru) | Лечебно-профилактическое средство "эйхлофил", его применение и способ профилактики и лечения заболеваний | |
| CN1093421C (zh) | 一种治疗乙肝鼻闻药剂的制备方法 | |
| Isakjonovich | THE EFFECT OF MEDICINAL PLANTS ON THE INFLAMMATORY PROCESS | |
| Yamakage et al. | Effects of the Chinese herbal medicines Bupleuri radix, Ginseng radix, and Zingiberis rhizoma on lymphatic vessel activity in rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Yang Hui Document name: Third notice of examination advice |
|
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1041413 Country of ref document: HK |